Hereditary angioedema (HAE) is a rare but debilitating and potentially fatal disease that presents in various forms, and can be difficult to manage. Its underlying cause is mutations in a gene that, through its protein product, controls production of the tissue enzyme kallikrein and a peptide mediator, bradykinin. The resulting overproduction of bradykinin leads to increased vascular permeability and oedema.

During the COVID-19 pandemic, frequent handwashing and disinfection have exacerbated or caused skin diseases. This case report shows the simultaneous development of allergic contact dermatitis to Kathon CG (DuPoint, Wilmington, Delaware, USA), Euxyl K400, and fragrance mix I because of the frequent use of moist (baby) wipes during the pandemic outbreak.

Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic condition, whereby patients present with recurrent episodes of swelling. This affects the subcutaneous and submucosal tissues of the skin as well as mucous membranes such as the respiratory and gastrointestinal tracts.

The identification of pathological elements that drive disease progression, so-called regulators, is essential when studying progressive diseases.

Digestive Disease Week (DDW) 2022 was held both in San Diego, California, USA, and virtually. The meeting featured cutting-edge research and education in the field of gastroenterology, of which eight treatment-related presentations are summarised in this article.

THE CURTAIN OPENED on the 8th European Academy of Neurology (EAN) 2022 Congress on 25th June 2022 in Vienna, Austria, with EAN President Claudio Bassetti welcoming more than 8,000 neurologists from around the world.

MLD is caused by an accumulation of sulfatides in various organs and predominantly the central nervous system (CNS). Patients have an initial period of normal development, then experience developmental delay or stagnation (Figure 1).

In glioblastoma (GB), patients’ reliable response assessment criteria are crucial in order to accurately compare the responsiveness of different therapies in clinical trials, and to differentiate between therapy-induced changes and true tumour progression.